-
2
-
-
77953175143
-
-
National Cancer Institute. In 2010 edition. Bethesda, MD. Available from:
-
Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. In 2010 edition. Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975-2007/
-
SEER Cancer Statistics Review, 1975-2007
-
-
Altekruse, S.1
Kosary, C.2
Krapcho, M.3
-
3
-
-
0037408455
-
Determining the clinical course and outcome in chronic lymphocytic leukemia
-
DOI 10.1056/NEJMe030032
-
Rai KR, Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 2003;7:1797-9 (Pubitemid 36514711)
-
(2003)
New England Journal of Medicine
, vol.348
, Issue.18
, pp. 1797-1799
-
-
Rai, K.R.1
Chiorazzi, N.2
-
4
-
-
36448982918
-
Oblimersen for the treatment of patients with chronic lymphocytic leukemia
-
Cheson BD. Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Ther Clin Risk Manag 2007;3:855-70 (Pubitemid 350162084)
-
(2007)
Therapeutics and Clinical Risk Management
, vol.3
, Issue.5
, pp. 855-870
-
-
Cheson, B.D.1
-
5
-
-
45149100665
-
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
-
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-56
-
(2008)
Blood
, vol.111
, pp. 5446-5456
-
-
Hallek, M.1
Cheson, B.D.2
Catovsky, D.3
-
6
-
-
33947541773
-
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997
-
DOI 10.1200/JCO.2006.08.0762
-
Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793-8 (Pubitemid 350002879)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.7
, pp. 793-798
-
-
Flinn, I.W.1
Neuberg, D.S.2
Grever, M.R.3
Dewald, G.W.4
Bennett, J.M.5
Paietta, E.M.6
Hussein, M.A.7
Appelbaum, F.R.8
Larson, R.A.9
Moore Jr., D.F.10
Tallman, M.S.11
-
7
-
-
34447530283
-
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial
-
DOI 10.1016/S0140-6736(07)61125-8, PII S0140673607611258
-
Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 2007;370:230-9 (Pubitemid 47069536)
-
(2007)
Lancet
, vol.370
, Issue.9583
, pp. 230-239
-
-
Catovsky, D.1
Richards, S.2
Matutes, E.3
Oscier, D.4
Dyer, M.5
Bezares, R.6
Pettitt, A.7
Hamblin, T.8
Milligan, D.9
Child, J.10
Hamilton, M.11
Dearden, C.12
Smith, A.13
Bosanquet, A.14
Davis, Z.15
Brito-Babapulle, V.16
Else, M.17
Wade, R.18
Hillmen, P.19
-
8
-
-
31544434508
-
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
-
DOI 10.1182/blood-2005-06-2395
-
Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-91 (Pubitemid 43156283)
-
(2006)
Blood
, vol.107
, Issue.3
, pp. 885-891
-
-
Eichhorst, B.F.1
Busch, R.2
Hopfinger, G.3
Pasold, R.4
Hensel, M.5
Steinbrecher, C.6
Siehl, S.7
Jager, U.8
Bergmann, M.9
Stilgenbauer, S.10
Schweighofer, C.11
Wendtner, C.M.12
Dohner, H.13
Brittinger, G.14
Emmerich, B.15
Hallek, M.16
-
9
-
-
0037220152
-
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from cancer and leukemia group B 9712 (CALGB 9712)
-
DOI 10.1182/blood-2002-04-1258
-
Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14 (Pubitemid 36025880)
-
(2003)
Blood
, vol.101
, Issue.1
, pp. 6-14
-
-
Byrd, J.C.1
Peterson, B.L.2
Morrison, V.A.3
Park, K.4
Jacobson, R.5
Hoke, E.6
Vardiman, J.W.7
Rai, K.8
Schiffer, C.A.9
Larson, R.A.10
-
10
-
-
23044510136
-
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
-
DOI 10.1200/JCO.2005.12.051
-
Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88 (Pubitemid 46211313)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.18
, pp. 4079-4088
-
-
Keating, M.J.1
O'Brien, S.2
Albitar, M.3
Lerner, S.4
Plunkett, W.5
Giles, F.6
Andreeff, M.7
Cortes, J.8
Faderl, S.9
Thomas, D.10
Koller, C.11
Wierda, W.12
Detry, M.A.13
Lynn, A.14
Kantarjian, H.15
-
11
-
-
70449723145
-
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen
-
O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009;27:5208-12
-
(2009)
J Clin Oncol
, vol.27
, pp. 5208-5212
-
-
O'Brien, S.1
Moore, J.O.2
Boyd, T.E.3
-
12
-
-
77950524161
-
Improving FCR immunochemotherapy in CLL
-
Robak T. Improving FCR immunochemotherapy in CLL. Blood 2010;115:437-8
-
(2010)
Blood
, vol.115
, pp. 437-438
-
-
Robak, T.1
-
13
-
-
34548490096
-
New treatments for chronic lymphocytic leukemia
-
DOI 10.1007/s11912-007-0047-7
-
Chanan-Khan AA. New treatments for chronic lymphocytic leukemia. Curr Oncol Rep 2007;9:353-60 (Pubitemid 47377066)
-
(2007)
Current Oncology Reports
, vol.9
, Issue.5
, pp. 353-360
-
-
Chanan-Khan, A.A.1
-
14
-
-
0026696155
-
Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells
-
Schena M, Larsson LG, Gottardi D, et al. Growth- and differentiation- associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992;79:2981-9
-
(1992)
Blood
, vol.79
, pp. 2981-9
-
-
Schena, M.1
Larsson, L.G.2
Gottardi, D.3
-
15
-
-
0027239823
-
Bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
-
Hanada M, Delia D, Aiello A, et al. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82:1820-8 (Pubitemid 23278773)
-
(1993)
Blood
, vol.82
, Issue.6
, pp. 1820-1828
-
-
Hanada, M.1
Delia, D.2
Aiello, A.3
Stadtmauer, E.4
Reed, J.C.5
-
16
-
-
19944405795
-
Expression of the NF-κB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively
-
DOI 10.1002/path.1768
-
Tracey L, Perez-Rosado A, Artiga MJ, et al. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2005;206:123-34 (Pubitemid 40754015)
-
(2005)
Journal of Pathology
, vol.206
, Issue.2
, pp. 123-134
-
-
Tracey, L.1
Perez-Rosado, A.2
Artiga, M.J.3
Camacho, F.I.4
Rodriguez, A.5
Martinez, N.6
Ruiz-Ballesteros, E.7
Mollejo, M.8
Martinez, B.9
Cuadros, M.10
Garcia, J.F.11
Lawler, M.12
Piris, M.A.13
-
17
-
-
0029871942
-
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome
-
Robertson LE, Plunkett W, McConnell K, et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996;10:456-9 (Pubitemid 26128784)
-
(1996)
Leukemia
, vol.10
, Issue.3
, pp. 456-459
-
-
Robertson, L.E.1
Plunkett, W.2
McConnell, K.3
Keating, M.J.4
McDonnell, T.J.5
-
18
-
-
0036971988
-
Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients
-
Klobusicka M, Kusenda J, Babusikova O. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients. Neoplasma 2002;49:387-93 (Pubitemid 36139239)
-
(2002)
Neoplasma
, vol.49
, Issue.6
, pp. 387-393
-
-
Klobusicka, M.1
Kusenda, J.2
Babusikova, O.3
-
19
-
-
1542713470
-
Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation
-
DOI 10.1038/sj.leu.2403231
-
Menendez P, Vargas A, Bueno C, et al. Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia 2004;18:491-8 (Pubitemid 38425863)
-
(2004)
Leukemia
, vol.18
, Issue.3
, pp. 491-498
-
-
Menendez, P.1
Vargas, A.2
Bueno, C.3
Barena, S.4
Almeida, J.5
De Santiago, M.6
Lopez, A.7
Roa, S.8
San Miguel, J.F.9
Orfao, A.10
-
20
-
-
0034071909
-
Expression of bcl-2 and bax in cells isolated from B-chronic lymphocytic leukemia patients at different stages of the disease
-
DOI 10.1034/j.1600-0609.2000.90042.x
-
Aviram A, Rabizadeh E, Zimra Y, et al. Expression of bcl-2 and bax in cells isolated from B-chronic lymphocytic leukemia patients at different stages of the disease. Eur J Haematol 2000;64:80-4 (Pubitemid 30167138)
-
(2000)
European Journal of Haematology
, vol.64
, Issue.2
, pp. 80-84
-
-
Aviram, A.1
Rabizadeh, E.2
Zimra, Y.3
Yeshoron, M.4
Marmelstein, M.5
Shaklai, M.6
Bairey, O.7
-
21
-
-
7144259736
-
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine
-
Zaja F, Di Loreto C, Amoroso V, et al. BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxyadenosine. Leuk Lymphoma 1998;28:567-72 (Pubitemid 28203907)
-
(1998)
Leukemia and Lymphoma
, vol.28
, Issue.5-6
, pp. 567-572
-
-
Zaja, F.1
Loreto, C.D.I.2
Amoroso, V.3
Salmaso, F.V.4
Russo, D.5
Silvestri, F.6
Fanin, R.7
Damianp, D.8
Infanti, L.9
Mariuzzi, L.10
Beltrami, C.A.11
Baccarani, M.12
-
22
-
-
0031981143
-
Mechanisms of Bcl-2 protein function
-
Wang HG, Reed JC. Mechanisms of Bcl-2 protein function. Histol Histopathol 1998;13:521-30
-
(1998)
Histol Histopathol
, vol.13
, pp. 521-530
-
-
Wang, H.G.1
Reed, J.C.2
-
23
-
-
0031464448
-
Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies
-
Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997;34:9-19 (Pubitemid 28032415)
-
(1997)
Seminars in Hematology
, vol.34
, Issue.SUPPL. 5
, pp. 9-19
-
-
Reed, J.C.1
-
24
-
-
0029897734
-
Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX
-
McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996;156:2624-30 (Pubitemid 26091593)
-
(1996)
Journal of Immunology
, vol.156
, Issue.7
, pp. 2624-2630
-
-
McConkey, D.J.1
Chandra, J.2
Wright, S.3
Plunkett, W.4
McDonnell, T.J.5
Reed, J.C.6
Keating, M.7
-
25
-
-
0029978058
-
Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance
-
Thomas A, El Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996;12:1055-62 (Pubitemid 26104447)
-
(1996)
Oncogene
, vol.12
, Issue.5
, pp. 1055-1062
-
-
Thomas, A.1
El Rouby, S.2
Reed, J.C.3
Krajewski, S.4
Silber, R.5
Potmesil, M.6
Newcomb, E.W.7
-
27
-
-
25444520537
-
MiR-15 and miR-16 induce apoptosis by targeting BCL2
-
DOI 10.1073/pnas.0506654102
-
Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-9 (Pubitemid 41377683)
-
(2005)
Proceedings of the National Academy of Sciences of the United States of America
, vol.102
, Issue.39
, pp. 13944-13949
-
-
Cimmino, A.1
Calin, G.A.2
Fabbri, M.3
Iorio, M.V.4
Ferracin, M.5
Shimizu, M.6
Wojcik, S.E.7
Aqeilan, R.I.8
Zupo, S.9
Dono, M.10
Rassenti, L.11
Alder, H.12
Volinia, S.13
Liu, C.-G.14
Kipps, T.J.15
Negrini, M.16
Croce, C.M.17
-
28
-
-
27244434788
-
A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia
-
DOI 10.1056/NEJMoa050995
-
Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801 (Pubitemid 41549891)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.17
, pp. 1793-1801
-
-
Calin, G.A.1
Ferracin, M.2
Cimmino, A.3
Di Leva, G.4
Shimizu, M.5
Wojcik, S.E.6
Iorio, M.V.7
Visone, R.8
Sever, N.I.9
Fabbri, M.10
Iuliano, R.11
Palumbo, T.12
Pichiorri, F.13
Roldo, C.14
Garzon, R.15
Sevignani, C.16
Rassenti, L.17
Alder, H.18
Volinia, S.19
Liu, C.-G.20
Kipps, T.J.21
Negrini, M.22
Croce, C.M.23
more..
-
29
-
-
0036720390
-
Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1
-
Pedersen IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002;100:1795-801 (Pubitemid 34925159)
-
(2002)
Blood
, vol.100
, Issue.5
, pp. 1795-1801
-
-
Pedersen, I.M.1
Kitada, S.2
Leoni, L.M.3
Zapata, J.M.4
Karras, J.G.5
Tsukada, N.6
Kipps, T.J.7
Choi, Y.S.8
Bennett, F.9
Reed, J.C.10
-
30
-
-
0034667624
-
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1
-
Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-63
-
(2000)
Blood
, vol.96
, pp. 2655-2663
-
-
Burger, J.A.1
Tsukada, N.2
Burger, M.3
-
31
-
-
23944488816
-
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
-
DOI 10.1182/blood-2004-12-4918
-
Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005;106:1824-30 (Pubitemid 41208600)
-
(2005)
Blood
, vol.106
, Issue.5
, pp. 1824-1830
-
-
Burger, M.1
Hartmann, T.2
Krome, M.3
Rawluk, J.4
Tamamura, H.5
Fujii, N.6
Kipps, T.J.7
Burger, J.A.8
-
32
-
-
23044514711
-
Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α
-
DOI 10.1182/blood-2004-03-0889
-
Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005;106:1012-20 (Pubitemid 41076448)
-
(2005)
Blood
, vol.106
, Issue.3
, pp. 1012-1020
-
-
Nishio, M.1
Endo, T.2
Tsukada, N.3
Ohata, J.4
Kitada, S.5
Reed, J.C.6
Zvaifler, N.J.7
Kipps, T.J.8
-
33
-
-
0036272536
-
Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL)
-
DOI 10.1038/sj/leu/2402540
-
Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002;16:1045-52 (Pubitemid 34618843)
-
(2002)
Leukemia
, vol.16
, Issue.6
, pp. 1045-1052
-
-
Faderl, S.1
Keating, M.J.2
Do, K.-A.3
Liang, S.-Y.4
Kantarjian, H.M.5
O'Brien, S.6
Garcia-Manero, G.7
Manshouri, T.8
Albitar, M.9
-
34
-
-
15244355253
-
Bcl-2 antisense therapy in B-cell malignancies
-
DOI 10.1016/j.blre.2004.11.002
-
Chanan-Khan A. Bcl-2 antisense therapy in B-cell malignancies. Blood Rev 2005;19:213-21 (Pubitemid 40387412)
-
(2005)
Blood Reviews
, vol.19
, Issue.4
, pp. 213-221
-
-
Chanan-Khan, A.1
-
35
-
-
28844454167
-
Antisense strategies for oncogene inactivation
-
DOI 10.1053/j.seminoncol.2005.09.003, PII S0093775405003623, Gene Therapy of Cancer
-
Stein CA, Benimetskaya L, Mani S. Antisense strategies for oncogene inactivation. Semin Oncol 2005;32:563-72 (Pubitemid 41772684)
-
(2005)
Seminars in Oncology
, vol.32
, Issue.6
, pp. 563-572
-
-
Stein, C.A.1
Benimetskaya, L.2
Mani, S.3
-
36
-
-
0042398462
-
BCL-2 antisense therapy: In vitro, in vivo and human trial experiences in haematological malignancies
-
Cotter F. BCL-2 antisense therapy: in vitro, in vivo and human trial experiences in haematological malignancies. Naunyn-Schmiedebergs Arch Pharmacol 1998;358(Suppl 1):205
-
(1998)
Naunyn-Schmiedebergs Arch Pharmacol
, vol.358
, Issue.SUPPL. 1
, pp. 205
-
-
Cotter, F.1
-
37
-
-
34248157136
-
Phase I trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: A Children's Oncology Group study
-
DOI 10.1200/JCO.2006.09.5125
-
Rheingold SR, Hogarty MD, Blaney SM, et al. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J Clin Oncol 2007;25:1512-18 (Pubitemid 46733077)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.12
, pp. 1512-1518
-
-
Rheingold, S.R.1
Hogarty, M.D.2
Blaney, S.M.3
Zwiebel, J.A.4
Sauk-Schubert, C.5
Chandula, R.6
Krailo, M.D.7
Adamson, P.C.8
-
38
-
-
0037438586
-
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
-
DOI 10.1182/blood-2002-06-1899
-
Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003;101:425-32 (Pubitemid 36077559)
-
(2003)
Blood
, vol.101
, Issue.2
, pp. 425-432
-
-
Marcucci, G.1
Byrd, J.C.2
Dai, G.3
Klisovic, M.I.4
Kourlas, P.J.5
Young, D.C.6
Cataland, S.R.7
Fisher, D.B.8
Lucas, D.9
Chan, K.K.10
Porcu, P.11
Lin, Z.-P.12
Farag, S.F.13
Frankel, S.R.14
Zwiebel, J.A.15
Kraut, E.H.16
Balcerzak, S.P.17
Bloomfield, C.D.18
Grever, M.R.19
Caligiuri, M.A.20
more..
-
39
-
-
20644469046
-
Phase i study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity
-
Marcucci G, Stock W, Dai G, et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 2005;23:3404-11
-
(2005)
J Clin Oncol
, vol.23
, pp. 3404-3411
-
-
Marcucci, G.1
Stock, W.2
Dai, G.3
-
40
-
-
84871473548
-
A pharmacokinetic (PK) study of oblimersen sodium (G3139) + dacarbazine (DTIC) in patients with metastatic melanoma (MM)
-
American Society of Clinical Oncologists; 31 May - 3 Jun 2003; Chicago, Illinois, United States. J Clin Oncol
-
Demidov LV, Kharkevitch G, Itri LM, Frankel SR. A pharmacokinetic (PK) study of oblimersen sodium (G3139) + dacarbazine (DTIC) in patients with metastatic melanoma (MM). Proceedings of the 39th Annual Meeting, American Society of Clinical Oncologists; 31 May - 3 Jun 2003; Chicago, Illinois, United States. J Clin Oncol 2003;22:156
-
(2003)
Proceedings of the 39th Annual Meeting
, vol.22
, pp. 156
-
-
Demidov, L.V.1
Kharkevitch, G.2
Itri, L.M.3
Frankel, S.R.4
-
41
-
-
21044431880
-
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer
-
DOI 10.1158/1078-0432.CCR-04-2145
-
Tolcher AW, Chi K, Kuhn J, et al. A Phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005;11:3854-61 (Pubitemid 40685606)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.10
, pp. 3854-3861
-
-
Tolcher, A.W.1
Chi, K.2
Kuhn, J.3
Gleave, M.4
Patnaik, A.5
Takimoto, C.6
Schwartz, G.7
Thompson, I.8
Berg, K.9
D'Aloisio, S.10
Murray, N.11
Frankel, S.R.12
Izbicka, E.13
Rowinsky, E.14
-
42
-
-
32944475363
-
Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia
-
DOI 10.1200/JCO.2005.02.4364
-
O'Brien SM, Cunningham CC, Golenkov AK, et al. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005;23:7697-702 (Pubitemid 46291834)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.30
, pp. 7697-7702
-
-
O'Brien, S.M.1
Cunningham, C.C.2
Golenkov, A.K.3
Turkina, A.G.4
Novick, S.C.5
Rai, K.R.6
-
43
-
-
0035992688
-
Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment
-
Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002;12:193-213 (Pubitemid 34815931)
-
(2002)
Antisense and Nucleic Acid Drug Development
, vol.12
, Issue.3
, pp. 193-213
-
-
Klasa, R.J.1
Gillum, A.M.2
Klem, R.E.3
Frankel, S.R.4
-
45
-
-
79960971061
-
Bcl-2 antisense (genasense™) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL Cells
-
Auer R, Corbo M, Fegan C. Bcl-2 antisense (Genasense ) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells [abstract 3358]. Proceedings of the 43rd Annual Meeting. Am Soc Hematol Blood 2001;98:808a (Pubitemid 33790617)
-
(2001)
Blood
, vol.98
, Issue.PART 1
-
-
Auer, R.L.1
Corbo, M.2
Fegan, C.D.3
Frankel, S.R.4
Cotter, F.E.5
-
46
-
-
0009794598
-
Manipulation of differentially expressed genes such as bcl-2 leads to increased killing of B chronic lymphocytic leukemia [abstract 3547]
-
Joshi S, Wang P, Dickinson J. Manipulation of differentially expressed genes such as bcl-2 leads to increased killing of B chronic lymphocytic leukemia [abstract 3547]. Proc Am Assoc Cancer Res 2001;42:659
-
(2001)
Proc Am Assoc Cancer Res
, vol.42
, pp. 659
-
-
Joshi, S.1
Wang, P.2
Dickinson, J.3
-
47
-
-
33745312907
-
Efficacy and Safety of the Combination of Genasense (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia
-
Mavromatis B, Rai KR, Wallace PK, et al. Efficacy and Safety of the Combination of Genasense (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 2005;106:2129
-
(2005)
ASH Annual Meeting Abstracts
, vol.106
, pp. 2129
-
-
Mavromatis, B.1
Rai, K.R.2
Wallace, P.K.3
-
48
-
-
79956084877
-
Impact of prognostic markers on outcomes in patients with advanced chronic lymphocytic leukemia treated with the regimen of fludarabine/ rituximab plus oblimersen (Bcl-2 Antisense) [abstract 6609]. 2006
-
Marvromatis B, Rai K, Wallace PK, et al. Impact of prognostic markers on outcomes in patients with advanced chronic lymphocytic leukemia treated with the regimen of fludarabine/ rituximab plus oblimersen (Bcl-2 Antisense) [abstract 6609]. 2006 ASCO Annual Meeting Proceedings; 2006. p. 24
-
(2006)
ASCO Annual Meeting Proceedings
, pp. 24
-
-
Marvromatis, B.1
Rai, K.2
Wallace, P.K.3
-
49
-
-
36448950375
-
Chemotherapy with or without oblimersen sodium (Bcl-2 antisense; Genasense ; G3139) in advanced chronic lymphocytic leukemia: Report of a large randomized study
-
Rai KR, Moore J, Boyd TE. Chemotherapy with or without oblimersen sodium (Bcl-2 antisense; Genasense ; G3139) in advanced chronic lymphocytic leukemia: report of a large randomized study. Leuk Lymphoma 2005;46(Suppl 1):S16
-
(2005)
Leuk Lymphoma
, vol.46
, Issue.SUPPL. 1
-
-
Rai, K.R.1
Moore, J.2
Boyd, T.E.3
-
50
-
-
34047217206
-
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
-
DOI 10.1200/JCO.2006.07.1191
-
O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007;25:1114-20 (Pubitemid 46596764)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.9
, pp. 1114-1120
-
-
O'Brien, S.1
Moore, J.O.2
Boyd, T.E.3
Larratt, L.M.4
Skotnicki, A.5
Koziner, B.6
Chanan-Khan, A.A.7
Seymour, J.F.8
Bociek, R.G.9
Pavletic, S.10
Rai, K.R.11
|